Shandong Sito Bio-technology Co Ltd (300583) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥15.13 Million ≈ $2.21 Million USD) by net assets (CN¥1.80 Billion ≈ $263.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300583 equity financing ratio to measure how much of total assets are equity-financed.
Shandong Sito Bio-technology Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Shandong Sito Bio-technology Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Shandong Sito Bio-technology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Sito Bio-technology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HCK Capital Group Bhd
KLSE:7105
|
-0.259x |
|
Pollard Banknote Limited
TO:PBL
|
0.007x |
|
JiangXi BaiSheng Intelligent Technology Co. Ltd.
SHE:301083
|
N/A |
|
Guangzhou Echom Sci&Tech Co Ltd
SHE:002420
|
-0.033x |
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
-0.093x |
|
CHEERWIN GRP. -0000002
F:1RQ
|
N/A |
|
Suzhou Longjie Special Fiber Co Ltd
SHG:603332
|
-0.380x |
|
CPH Chemie und Papier Holding
SW:CPHN
|
0.145x |
Annual Cash Flow Conversion Efficiency for Shandong Sito Bio-technology Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Sito Bio-technology Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Shandong Sito Bio-technology Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.88 Billion ≈ $275.71 Million |
CN¥194.46 Million ≈ $28.46 Million |
0.103x | +329.60% |
| 2023-12-31 | CN¥2.07 Billion ≈ $302.24 Million |
CN¥-92.85 Million ≈ $-13.59 Million |
-0.045x | -154.77% |
| 2022-12-31 | CN¥1.77 Billion ≈ $259.14 Million |
CN¥145.34 Million ≈ $21.27 Million |
0.082x | -37.48% |
| 2021-12-31 | CN¥1.73 Billion ≈ $253.45 Million |
CN¥227.35 Million ≈ $33.27 Million |
0.131x | -12.80% |
| 2020-12-31 | CN¥1.69 Billion ≈ $247.50 Million |
CN¥254.60 Million ≈ $37.26 Million |
0.151x | +392.93% |
| 2019-12-31 | CN¥1.89 Billion ≈ $276.09 Million |
CN¥57.62 Million ≈ $8.43 Million |
0.031x | +117.00% |
| 2018-12-31 | CN¥1.86 Billion ≈ $272.45 Million |
CN¥-334.41 Million ≈ $-48.94 Million |
-0.180x | -2914.08% |
| 2017-12-31 | CN¥1.71 Billion ≈ $249.81 Million |
CN¥10.90 Million ≈ $1.59 Million |
0.006x | -95.20% |
| 2016-12-31 | CN¥603.01 Million ≈ $88.24 Million |
CN¥80.15 Million ≈ $11.73 Million |
0.133x | -22.69% |
| 2015-12-31 | CN¥506.66 Million ≈ $74.14 Million |
CN¥87.10 Million ≈ $12.75 Million |
0.172x | -71.35% |
| 2014-12-31 | CN¥290.80 Million ≈ $42.55 Million |
CN¥174.49 Million ≈ $25.53 Million |
0.600x | +137.69% |
| 2013-12-31 | CN¥98.83 Million ≈ $14.46 Million |
CN¥24.95 Million ≈ $3.65 Million |
0.252x | +126.87% |
| 2012-12-31 | CN¥32.47 Million ≈ $4.75 Million |
CN¥-30.50 Million ≈ $-4.46 Million |
-0.939x | -- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more